The Mannan-binding lectin serine protease (MASP) protein family is critical for the complement pathway in the immune system.

In addition to its lectin pathway inhibitors, the company is advancing its development of antibodies and small-molecule inhibitors against MASP-3 to block activation of the alternative pathway.

MASP-2, the lectin pathway’s effector enzyme and the target for narsoplimab, binds the nucleocapsid protein of severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) – the ...

Three pathways have now been described in the complement system — the classic, alternative and lectin. A fourth, lytic pathway is added by some authors for membrane attack complex.

Its pathogenesis is complex and not well understood, but there is increasing evidence that the lectin-driven complement activation may be behind it. Mannose-binding lectin serine protease 2 (MASP-2) ...

In COVID-19, activation of the lectin pathway is a very early event, occurring prior to hyperinflammation and the innate antibody response.

The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and ...

OMS906 is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway.